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Aims: Randomised controlled trials demonstrate that using flash glucose monitoring
improves glycaemic control but it is unclear whether this applies outside trial conditions.
We investigated glucose testing patterns in users worldwide under real life settings to
establish testing frequency and association with glycaemic parameters.
Methods: Glucose results were de-identified and uploaded onto a dedicated database once
readers were connected to an internet-ready computer. Data between September 2014 and
May 2016, comprising 50,831 readers and 279,446 sensors worldwide, were analysed. Scan
rate per reader was determined and each reader was sorted into twenty equally-sized rank-
ordered groups, categorised by scan frequency. Glucose parameters were calculated for
each group, including estimated HbA1c, time above, below and within range identified as
3.9–10.0 mmol/L.
Results: Users performed a mean of 16.3 scans/day [median (IQR): 14 (10–20)] with 86.4
million hours of readings and 63.8 million scans. Estimated HbA1c gradually reduced from
8.0% to 6.7% (64 to 50 mmol/mol) as scan rate increased from lowest to highest scan groups
(4.4 and 48.1 scans/day, respectively; p < .001). Simultaneously, time below 3.9, 3.1 and 2.5
mmol/L decreased by 15%, 40% and 49%, respectively (all p < .001). Time above 10.0 mmol/L
decreased from 10.4 to 5.7 h/day (44%, p < .001) while time in range increased from 12.0 to
16.8 h/day (40%, p < .001). These patterns were consistent across different countries.
Conclusions: In real-world conditions, flash glucose monitoring allows frequent glucose
checks with higher rates of scanning linked to improved glycaemic markers, including
increased time in range and reduced time in hyper and hypoglycaemia.
 2017 Abbott Diabetes Care. Published by Elsevier Ireland Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Hayter),
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Diabetes is reaching epidemic proportions and managing gly-
caemia is key to prevent microvascular complications as well
as long-term macrovascular disease [1–5]. HbA1c remains the
gold standard for monitoring glycaemic control and given the
detrimental effects of hyperglycaemia, guidelines recom-
mend tight HbA1c targets [6]. However, treatment of hypergly-
caemia can precipitate hypoglycaemia, particularly in
insulin-treated patients, which is associated with adverse
clinical outcome [7–11].
Self-monitoring of blood glucose (SMBG) in diabetes is
essential for safe and effective adjustment of glycaemic ther-
apy in insulin treated patients [12–14]. Although a higher rate
of glucose testing (in excess of 8 times/day) is associated with
improved glycaemic control [15,16], repeated daily glucose
checks are painful, inconvenient and can be difficult to main-
tain long-term. A recent UK-based analysis of pharmacy
records reported 2.1 tests per day for those using insulin
[17], whereas in those using modern blood glucose meters
and sophisticated cloud-based analysis software, rates of
testing range between 2.5 and 5.5 per day across Europe and
North America [18].
Continuous glucose monitoring (CGM) is an alternative to
SMBG, but the use of conventional CGM has been limited
due to the need for repeated calibration using capillary glu-
cose testing, relatively short sensor life and high costs. How-
ever, the emergence of FreeStyle LibreTM (Abbott Diabetes Care,
Witney, UK) flash glucose monitor, a new generation of glu-
cose testing devices, has made glucose checks easier with
the ability to scan a sensor for glucose reading at any time.
The flash glucose monitoring system does not require calibra-
tion, has a long sensor lifetime of 14 days and is relatively
affordable, explaining the proliferation in device use.
Randomised controlled trials in patients with diabetes
have shown increased glucose testing frequency with flash
glucose monitoring, which was associated with improved gly-
caemic markers; a reduction in hypoglycaemia was observed
in both type 1 and type 2 diabetes mellitus patients. The
reduction in hypoglycaemia was evident whilst maintaining
good HbA1c in type 1 diabetes mellitus patients, whereas in
younger type 2 diabetes mellitus patients with inadequate
glycaemic control it was associated with the added benefit
of decreasing HbA1c [19,20]. The improvement in hypogly-
caemia was observed early with flash glucose monitoring
use [19,20]. Furthermore, these studies indicated high patient
acceptability and satisfaction with the system [19,20].
Whilst data from these trials are encouraging, it remains
unclear whether these findings apply outside trial conditions.
Therefore, our overall aim was to investigate the use of flash
glucose monitoring in real life clinical practice worldwide
over a period of 20 months to establish: (i) number of glucose
checks and their pattern across the day, (ii) associations
between glucose testing frequency and glycaemic markers,
(iii) potential geographical differences in glycaemic parame-
ters and (iv) evolution of glycaemic markers during first sen-
sor use.2. Materials and methods
2.1. Sensors and readers
The FreeStyle Libre system is a sensor-based glucose monitor,
with an on-body patch and a sensor filament in the subcuta-
neous tissue that measures interstitial fluid glucose levels
and remains in situ for up to two weeks. A dedicated reader
is placed over the on-body patch to wirelessly collect the cur-
rent glucose and glucose trend, along with up to 8 h of glucose
readings which are automatically stored every 15 min. When
connected to the PC-based software with an active internet
connection, the reader’s 90-day memory is de-identified and
uploaded to a database, the contents of which were analysed
for this study. The commercial availability (from a webshop
for approximately 70 euro for the single reader and 70 euro
per 14-day sensor) of the system began in September 2014
in seven European countries (Germany, United Kingdom,
France, Italy, Spain, Sweden and Netherlands), and subse-
quently expanded to other countries. The report software
was also available for free download, which included an
agreement that de-identified data would be collected by a
database at each internet-connected use of the software.
From September 2014 to May 2016, this database collected
data from 55,343 readers with 64,288,918 sensor scans and
392,187,678 automatically-stored glucose readings.
2.2. Scanning details
Scanning frequency for each sensor was calculated by count-
ing the number of scans divided by duration of sensor use
according to recorded start and end times. Scanning fre-
quency per reader was assessed by calculating mean scans
of all its sensors followed by determining cumulative fre-
quency distribution and summary metrics (mean, median
and IQR). To understand the daily patterns of scanning, fre-
quency of scans by hour of the day was evaluated.
2.3. Glycaemic measures analysed
The analysis required each sensor have at least 120 h of
automatically-stored readings (480 readings) to ensure reli-
able glucose control measures. Data from all sensors belong-
ing to the same reader were combined and calculated as the
mean of all sensor measures. The readers were rank-
ordered by scan frequency and allocated to twenty equally-
sized groups of 2542 readers each. Glucose measures assessed
included time in euglycaemic range (defined as glucose
between 3.9 and 10 mmol/L), time in hyperglycaemia (>10
mmol/L) and time in hypoglycaemia (<3.9 mmol/L). Hypogly-
caemia was further divided into subcategories of time spent
below 3.1 mmol/L or below 2.5 mmol/L, cut offs in accordance
with recent guidelines and publications in the field [19–23].
Finally, mean glucose was converted into estimated HbA1c
by the method accepted by international professional dia-
betes societies [24] and was also analysed. The glucose con-
trol measures were inspected as a function of the twenty
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scan frequency groups were evaluated.
2.4. Assessment of regional differences
The glucose check frequency and relationship to glycaemic
markers was evaluated across six different regions: five
included countries having the highest use of flash glucose
monitoring (Germany, Spain, France, UK and Italy), whereas
the last ‘‘region” grouped all remaining countries together.
Each reader was allocated to a country of origin determined
by the country-code element of the initial internet protocol
address of the software instance connected to the database,
and was utilised to examine regional differences in the rela-
tionships of glycaemic measures and scan frequency.
2.5. Change in glycaemic measures
Glucose metrics were evaluated by day of sensor use for all
days available for the first sensor. A subset of readers (n =
14,617) were selected that had sufficient measurements for
their first, second, and third sensors (at least 240 h for all
three) and were used consecutively (within 24 h). The daily
glycaemic metrics of the first sensor were adjusted by day
to correct for any systematic artifacts by sensor day.
2.6. Statistical analysis
The cumulative frequency of scan rates were calculated for
each five percent of available readers, and descriptive statis-
tics were calculated. The frequency distribution of scans by
hour of the day was inspected for scanning patterns across
the day.
Given the large number of readers, twenty equally-sized
groups, divided along scan rate, were analysed by descriptive
measures (mean and standard error) of glycaemic metrics.
Statistical comparisons across the groups were performed
by one-way analysis of variance (ANOVA), and the span of gly-
caemic measures and relative changes were reported from
the lowest to highest scan rate groups.
For the analysis by region, ten scan rate groups were anal-
ysed due to the smaller numbers of available readers in the
regional subgroups, but were otherwise evaluated similarly.
ANOVA was done for mean rates of scanning and hypogly-
caemia across the geographic regions and used for statistical
comparisons by day of glycaemic measures across the first 14
days of sensor use.
The database was analysed by structured query language
routines, and further summarized by KNIME (www.knime.
org) and R statistical package (www.r-project.org). In view of
the large sample size and multiple comparisons, only P < .01
was considered statistically significant. Confidence intervals
were calculated for each group least square mean of each
measure for each scan rate group, and comparisons were
made across the scan groupings.3. Results
3.1. User base
The analysis set had 50,831 readers with 279,446 sensors
spanning 86.4 million monitoring hours (345.6 million
automatically-stored readings) and 63.8 million sensor scans.
The initial seven launch countries detailed above provided
93% of the readers in the analysis set. Germany was the most
frequent (46%), followed by Spain (11%), France (10%), United
Kingdom (8.8%), Italy (8.2%), Sweden (5.2%) and Netherlands
(3.8%). Austria (2.5%) and Belgium (0.9%) were the only other
countries with more than 0.5% of the readers, with the
remaining 4% collected from 37 different countries around
the world.
3.2. Frequency and pattern of glucose testing
Users of the readers performed an average of 16.3 and median
(IQR) of 14 (10–20) daily glucose scans (Fig. 1a). The mean
number of days of monitoring across the scan groups in the
analysis set averaged 70.8 days (range 38.5–82.0, Table 1).
The scanning occurred approximately five times more often
during typical awake hours (6 AM to midnight) compared
with typical sleeping periods (midnight to 6 AM). The most
frequent hour of the day for scanning was 8 PM, with the least
frequent at 3 AM. Despite lower scan rates at night, there was
still an average of 1.6 scans between midnight and 6 AM. The
pattern of daily scanning is shown in Fig. 1b.
3.3. Relationship between frequency of glucose testing and
glycaemic markers
The following glycaemic markers were analysed: estimated
HbA1c, time spent in euglycaemia (3.9–10.0 mmol/L), hyper-
glycaemia (>10.0 mmol/L) and hypoglycaemia (<3.9, <3.1,
and <2.5 mmol/L).
3.3.1. Estimated HbA1c
Estimated HbA1c reduced in groups with increasing number of
scans (Fig. 2a). At each end of the scale, those scanning on
average 4.4 times/day had an estimated HbA1c of 8.0% (95%
CI: 7.91–8.04%, 64 mmol/mol, 95% CI: 63–64 mmol/mol)
decreasing to 6.7% (95% CI: 6.66–6.75%, 50 mmol/mol, 95%
CI: 50–51 mmol/mol) in those performing an average of 48.1
scans/day (p < .001; Fig. 2a).
3.3.2. Time spent in hyperglycaemia
From the lowest to highest scan rate groups, time above 10.0
mmol/L decreased from 10.5 to 5.9 h/day, representing 44%
reduction (p < .001; Fig. 2b).
3.3.3. Time spent in euglycaemia
Time in range, defined as glucose levels between 3.9 and 10.0
mmol/L, increased from 12.0 to 16.8 h/day comparing lowest
Fig. 1 – Cumulative distribution of glucose check frequencies (A) and total number of scans by hour of day (B).
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time spent in euglycaemia (p < .001; Fig. 2c).
3.3.4. Time spent in hypoglycaemia
Time in hypoglycaemia was evaluated at three levels, in
accordance with recent guidance and reporting of ran-
domised controlled trials [19–23]. When low glucose levels
were defined as readings below 3.9 mmol/L, time in hypogly-
caemia decreased from 93.4 to 79.3 min per day comparing
the lowest with highest scan rate groups, representing a
15% reduction in exposure to hypoglycaemia (p < .001;
Fig. 2d). At a more extreme level of hypoglycaemia (<3.1
mmol/L), there was a 40% reduction comparing the lowest
to highest scan rate groups, with reduction from 43.4 to
26.2 min per day (p < .001, Fig. 2e). The most extreme hypogly-
caemic exposure (<2.5 mmol/L) had the largest relative reduc-
tion of 49% across the scale of scan rate frequency, from 23.4
to 11.9 min per day (p < .001, Fig. 2f).
3.4. Regional differences in scanning frequency and
relationship with glycaemic markers
We analysed whether the patterns described above remain
consistent in the different geographical regions.
3.4.1. Glucose scanning frequency
The scan frequency was found to vary significantly across the
regions (p < .001), with the UK having the highest daily scans
at 18.4. The scan rates across the regions all averaged over 16
per day, except France which had a scan frequency of 13.6 per
day (Fig. 3).
3.4.2. Relationship between scanning frequency and
glycaemic parameters
All countries showed a clear correlation between frequency of
glucose scans and reduction in both hyperglycaemia and
hypoglycaemia (Fig. 4). Moreover, increased scan frequency
was associated with longer time spent in range and lower
estimated HbA1c (Fig. 5).Although results were generally similar comparing the
various countries, some differences were observed. For exam-
ple, time spent in hypoglycaemia was most pronounced in
patients from France, followed by Spain, particularly in those
with less frequent scanning, whereas patients from Italy dis-
played the least hypoglycaemic exposure (p < .001).
The change in glucose levels, comparing low with high fre-
quency scanning groups, was most prominent in patients
from the UK, with time spent above 10.0 mmol/L decreasing
from 11 to 5 h/day, representing a 46% reduction in time spent
in hyperglycaemia. This was a more pronounced reduction
compared with Germany (40%), France (34%), Spain (32%)
and Italy (27%), respectively (p < .001). The decreased time
spent in hyperglycaemia for frequent users was associated
with decreased time spent in hypoglycaemia, emphasizing
both the efficacy and safety of frequent glucose scanning at
optimizing glycaemic control. When low glucose levels were
defined as those below 3.1 mmol/L, the ranking of the reduc-
tions across the regions were Spain (46%), Italy (45%), ‘‘Other”
(40%), France (32%), UK (30%) and Germany (26%).
3.5. Glycaemic markers during the initial 14 days of
system use
Within the first 14 days of sensor use, time in hyperglycaemia
and time in range were all found to be stable (Fig. 6a–c). How-
ever, reduction in hypoglycaemia was observed in the initial
days of use, with the most dramatic change being from the
first to second day. When low glucose levels were defined as
readings below 3.9 mmol/L, time in hypoglycaemia decreased
from 94.6 to 82.0 min per day from the first to fourteenth day
of use (p < .001), representing a 13% reduction in exposure to
hypoglycaemia (Fig. 6d). At a more extreme level of hypogly-
caemia (<3.1 mmol/L), there was a 23% reduction across the
two week period, with reduction from 36.3 to 27.9 min per
day (p < .001, Fig. 6e). The most extreme hypoglycaemic expo-
sure (<2.5 mmol/L) had the largest relative reduction of 32%
across fourteen day period, from 17.1 to 11.6 min per day
(p < .001, Fig. 6f). Furthermore, 74% of the reduction in time
Table 1 – Glucose control measures by scan rate group.
Scan rate
per day






Minutes per day below Hours per day Hours per day
2.5 mmol/L 3.1 mmol/L 3.9 mmol/L 3.9–10.0 mmol/L Above 10.0 mmol/L
4.4 (0.017) 2542 71.4 (1.6) 7.98 (0.033) 64 (0.3) 23.4 (0.80) 43.4 (1.20) 93.4 (1.99) 12.0 (0.10) 10.5 (0.10)
6.2 (0.007) 2542 78.4 (1.6) 7.74 (0.028) 61 (0.3) 23.0 (0.72) 43.7 (1.12) 96.7 (1.84) 12.5 (0.09) 9.9 (0.09)
7.4 (0.006) 2542 75.6 (1.6) 7.56 (0.026) 59 (0.3) 22.8 (0.70) 44.3 (1.09) 101.1 (1.86) 12.9 (0.08) 9.4 (0.09)
8.3 (0.005) 2542 79.3 (1.7) 7.56 (0.025) 59 (0.3) 20.8 (0.62) 41.3 (0.96) 97.3 (1.64) 13.0 (0.08) 9.4 (0.09)
9.2 (0.005) 2542 82.0 (1.7) 7.44 (0.025) 58 (0.3) 22.0 (0.67) 43.4 (1.05) 100.6 (1.81) 13.4 (0.08) 9.0 (0.09)
10 (0.005) 2542 80.7 (1.7) 7.38 (0.024) 57 (0.2) 19.5 (0.59) 39.8 (0.98) 97.8 (1.80) 13.6 (0.08) 8.7 (0.09)
10.8 (0.005) 2542 81.0 (1.6) 7.37 (0.023) 57 (0.2) 18.8 (0.57) 38.4 (0.93) 94.4 (1.66) 13.7 (0.08) 8.7 (0.08)
11.6 (0.005) 2542 80.8 (1.7) 7.28 (0.022) 56 (0.2) 18.6 (0.59) 38.1 (0.93) 95.7 (1.66) 14.1 (0.08) 8.4 (0.08)
12.4 (0.005) 2542 79.0 (1.7) 7.23 (0.022) 55 (0.2) 18.6 (0.58) 38.3 (0.96) 96.3 (1.74) 14.2 (0.08) 8.2 (0.08)
13.3 (0.005) 2542 78.3 (1.6) 7.22 (0.022) 55 (0.2) 17.4 (0.58) 36.5 (0.93) 94.2 (1.68) 14.3 (0.08) 8.1 (0.08)
14.2 (0.005) 2542 76.8 (1.7) 7.20 (0.022) 55 (0.2) 17.5 (0.56) 36.9 (0.92) 95.2 (1.68) 14.3 (0.08) 8.1 (0.08)
15.2 (0.006) 2542 73.5 (1.6) 7.15 (0.022) 55 (0.2) 17.5 (0.60) 36.6 (0.95) 94.9 (1.72) 14.6 (0.08) 7.8 (0.08)
16.4 (0.007) 2542 74.3 (1.6) 7.16 (0.022) 55 (0.2) 16.4 (0.52) 34.7 (0.87) 91.9 (1.65) 14.6 (0.08) 7.9 (0.08)
17.7 (0.008) 2542 68.3 (1.5) 7.08 (0.021) 54 (0.2) 17.1 (0.56) 36.3 (0.96) 94.4 (1.74) 14.8 (0.08) 7.6 (0.08)
19.1 (0.009) 2542 68.6 (1.5) 7.09 (0.022) 54 (0.2) 15.4 (0.53) 33.2 (0.88) 90.4 (1.65) 14.9 (0.08) 7.6 (0.08)
20.9 (0.011) 2542 62.3 (1.4) 7.01 (0.021) 53 (0.2) 15.4 (0.53) 32.7 (0.88) 89.5 (1.66) 15.2 (0.08) 7.3 (0.08)
23.1 (0.015) 2542 62.2 (1.4) 6.96 (0.021) 53 (0.2) 15.3 (0.58) 32.5 (0.95) 89.4 (1.78) 15.4 (0.08) 7.1 (0.08)
26.3 (0.021) 2542 55.1 (1.2) 6.91 (0.022) 52 (0.2) 14.2 (0.51) 30.9 (0.88) 87.4 (1.75) 15.7 (0.08) 6.8 (0.08)
31.5 (0.041) 2542 50.5 (1.2) 6.84 (0.023) 51 (0.2) 14.5 (0.56) 31.4 (0.98) 89.0 (1.94) 16.0 (0.08) 6.6 (0.09)
48.1 (0.300) 2533 38.5 (1.0) 6.70 (0.023) 50 (0.2) 11.9 (0.55) 26.2 (0.94) 79.3 (1.92) 16.8 (0.08) 5.9 (0.09)















































Fig. 2 – Glucose control measures by glucose check frequency.
Fig. 3 – Cumulative distribution of glucose check frequencies for different geographic regions.
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Fig. 4 – Glucose control measures for hyperglycaemia and hypoglycaemia by glucose check frequency for different geographic
regions.
Fig. 5 – Glucose control measures for estimated HbA1c and time in range by glucose check frequency for different geographic
regions.
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Fig. 6 – Glucose control measures by day for only the first sensor of each reader.
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with a further 26% reduction taking place over approximately
9 days, consistent with a rapid improvement.
4. Discussion
This is the first study to analyse the effects of flash glucose
monitoring, in over 50,000 users worldwide, on glycaemic
markers using a real world observational study design. Our
work provides a number of novel observations, including: (i)
a high frequency of glucose scanning compared to traditional
SMBG, (ii) a diurnal variation in scanning frequency is
observed with the majority undertaken between 6AM and
midnight, but relatively high rate of testing is still performed
overnight, (iii) higher scanning frequency is associated with
better glycaemic measures including lower estimated HbA1c,
decrease in time in hyper and hypoglycaemia and increased
time in euglycaemia with reduction in hypoglycaemic expo-
sure occurring early during sensor use, and (iv) the associa-
tions between frequency of glucose scans and improvement
in glycaemic parameters is consistent across different coun-
tries, although some subtle differences were evident related
to baseline and level change.
The observed high rate of glucose checks is explained by
the ease of testing and is consistent with data from two
recent randomised controlled trials. In a study in type 1 dia-
betes mellitus patients [19], mean scanning frequency was
15 times/day whereas in a study in type 2 diabetes mellitus
patients [20] it was lower at an average of 8 times/day. The
current study is also in agreement in finding the majority oftests conducted during the day, although a significant propor-
tion of tests were also performed overnight. No data on the
type of diabetes were available and therefore it is not possible
to ascertain whether a difference in scanning frequency is
evident in type 1 and type 2 diabetes mellitus patients in real
life clinical practice. A strong association between scanning
frequency and improved glycaemic parameters was observed,
which agrees with previous reports of increased frequency of
capillary glucose testing is associated with lower HbA1c
[15,16]. However, glucose scanning frequency with flash glu-
cose monitoring was significantly higher than SMBG checks
reported previously by almost four fold.
In addition to reduced hyperglycaemia, this work shows
that frequent scanning is simultaneously correlated with
decreased time spent in hypoglycaemia. The relationship
between hypoglycaemia and frequency of capillary glucose
testing is currently unclear, although CGM studies suggest
that a more thorough glucose profile helps to reduce hypogly-
caemic events [25,26]. Taken together, this indicates that the
frequent glucose data provided by flash glucose monitoring
is key to reducing hypoglycaemic events. The effects of this
glucose monitoring strategy on hypoglycaemia were found
to occur primarily early, within the first 48 h of sensor use, fol-
lowed by a further reduction in hypoglycaemia in the ensuing
week, which is consistent with the data reported by Bolinder
and colleagues [19]. Lowering glucose levels in diabetes is
associated with increased risk of hypoglycaemic events, but
as our work shows, those frequently testing glucose reduced
both hyper and hypoglycaemia. This clearly has important
clinical implications and suggests that flash monitor use
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and safely.
It was reassuring that the relationship between glucose
testing frequency and improvement in glycaemic markers
was consistent across various countries. However, some dif-
ferences were evident when analyzing the five countries with
the largest numbers of users. For example, the largest reduc-
tion in glucose levels, comparing lowwith high frequency glu-
cose scanners, was observed in patients from the UK,
whereas the least reduction between groups was found in
Italy. Time spent in hypoglycaemia was most pronounced in
patients from Spain and France with the least exposure in
Italy. However, increased scanning had the largest effect on
reducing hypoglycaemia in groups of patients from Spain
and the least reduction observed in groups of patients from
Germany. The clinical significance of these findings is not
entirely clear and these findings are best described as
hypothesis-generating. Future research is warranted to inves-
tigate potential regional glycaemic heterogeneity in detail.
The strengths of the current study include real life set-
tings, large sample size, broad geography and unrestricted
inclusion criteria. However, there are a number of limitations
that should be acknowledged. First, the basic characteristics
of patients including gender, age, type of diabetes, duration
of disease, and clinical parameters (including laboratory-
based HbA1c values) are unknown. Further characteristics
regarding employment profile, education, and socio-
economic status are not available. Diabetes management
self-efficacy markers and the methods and access to diabetes
counselling and behavior support are lacking. Therefore, dee-
per clinical or scientific observations within these relevant
subgroups are not possible. Second, there may be selection
bias by unknown factors like age, job profile or disease status
including towards those more motivated to improve gly-
caemia and those from higher socio-economic status, as the
flash monitoring device was likely self-funded by most of
the users. Third, the variability of scanning frequency from
first to subsequent sensor use is currently unknown and the
long-term effect of this monitoring strategy remains to be
investigated. Our study did not examine any long-term com-
plications that may be associated with use of the device, and
does not include any health economic impact assessment, as
these were beyond the scope of the analysis. Work is cur-
rently ongoing to collect longer-term longitudinal data on
patients using flash monitoring. Finally, the device has other
features that may have also contributed to our findings. The
arrow trend and 8-hour glucose history (32 glucose readings)
displayed by the reader, which are features not provided by
conventional SMBG devices, may have played a role in
improving glycaemic outcome. Moreover, the data transfer
indicates that users were likely to have reviewed daily traces
and summary reports of glucose patterns, including the
Ambulatory Glucose Profile [27], further helping to adjust
their therapies. These system features need further evalua-
tion with regard to successful integration into diabetes self-
care practices and therapy adjustments guided by clinicians.
Despite these short-comings, the work provides an expansive
view of the typical use of flash monitoring, and the substan-
tial clinical benefits observed in those who attend more fre-
quently to their glucose levels. Future work is still requiredto understand the role of flash glucose monitoring in modu-
lating patient behavior, such as adjusting diet and exercise,
and adherence to therapy as well as the ability to make self-
management decisions with insulin treatment.
This worldwide multinational database of over 50,000
users, 64.3 million glucose scans and 86.4 million hours of
automatic glucose monitoring provides an unprecedented
view into the usage of a new glucose monitoring technology.
The data demonstrate high frequency of scanning, emphasiz-
ing the ease by which glucose levels are checked. Moreover,
the work shows a strong correlation between the number of
glucose scans and improvement in glycaemic markers includ-
ing reduction in time spent in hypo and hyperglycaemia and
increased time in euglycaemia. This indicates that the system,
under real life settings, represents a powerful glucose moni-
toring strategy to improve glycaemia in patientswith diabetes.
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[16] Schütt M, Kern W, Krause U, et al. Is the frequency of self-
monitoring of blood glucose related to long-term metabolic
control? Multicenter analysis including 24,500 patients from
191 centers in Germany and Austria. Exp Clin Endocrinol
Diabetes 2006;114(7):384–8.
[17] Lee WC, Smith E, Chubb B, Wolden ML. Frequency of blood
glucose testing among insulin-treated diabetes mellituspatients in the United Kingdom. J Med Econ 2014;17
(3):167–75.
[18] Glooko+Diasend. Annual Diabetes Report 2016 Available
fromAvailable from: http://www.glooko.com, 2016 [accessed
February 22, 2017].
[19] Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J,
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